Cargando…
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135398/ https://www.ncbi.nlm.nih.gov/pubmed/27932891 http://dx.doi.org/10.2147/OTT.S100643 |